Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Carglumic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid
Details : Under the agreement, Eton Pharmaceuticals has acquired U.S. marketing rights to carglumic acid tablets. The product is an AB-rated, substitutable generic version of Carbaglu®.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 28, 2021
Lead Product(s) : Carglumic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : ANI Pharmaceuticals Inc
Deal Size : $372.5 million
Deal Type : Acquisition
Details : Novitium Pharma's lead drug, Acyclovir oral suspension, is a synthetic nucleoside analogue active against herpesviruses. The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and ...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $89.5 million
March 09, 2021
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : ANI Pharmaceuticals Inc
Deal Size : $372.5 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?